Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. PR Newswire LONDON, September 6, 2013 LONDON, September 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Thursday, September 5, 2013, the U.S. equity market posted gains. The S&P 500 gained 0.12%, while the Dow Jones Industrial Average and the NASDAQ Composite rose 0.04% and 0.27% respectively. Shares of companies in the healthcare sector ended on a mixed note, even as the broader market edged higher. The major movers included Celgene Corporation (NASDAQ: CELG), Edwards Lifesciences Corporation (NYSE: EW), Forest Laboratories Inc. (NYSE: FRX), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). AAAResearchReports.com has released free charting and technical research on these aforementioned companies. Register to read these reports at: http://www.aaaresearchreports.com/register/ Celgene Corporation's stock edged lower on Thursday, even as the broader market advanced. The company's shares closed the day 0.33% lower at$145.59after oscillating between$145.01 and $147.76. A total of 2.13 million shares were traded, which is below the daily average volume of 2.62 million. Despite Thursday's pullback, Celgene Corporation's shares have gained 4.01% in the previous three trading sessions and 29.76% in the last three months, outperforming the S&P 500 during both periods. Further, the company's stock is currently trading above its 50-day and 200-day averages of $135.20 and $112.40 respectively. Sign up for free report on CELG at: http://www.AAAResearchReports.com/CELG090613.pdf On Thursday, shares in Edwards Lifesciences Corporation gained 0.60%, extending their gains from previous trading sessions. The company's stock fluctuated between $71.24 and $72.31 to end the day at $71.79. A total of 0.70 million shares were traded, which is below the daily average volume of 1.03 million. Edwards Lifesciences Corporation's shares have gained 7.84% in the last three months, compared to a gain of 2.87% in the S&P 500 during the same period. Additionally, the company's stock is trading above its 50-day moving average of $69.74. EW free technical report can be accessed by signing up at: http://www.AAAResearchReports.com/EW090613.pdf On Thursday, Forest Laboratories Inc.'s stock fell by 0.14% from the previous day's closing price of $43.40, after rising sharply in the previous trading session. The company's shares ended the day at$43.34after fluctuating between$43.15 and$43.93. A total of 1.11 million shares were traded, which is below the daily average volume of 1.43 million. Despite Thursday's pullback, Forest Laboratories Inc.'s stock is up 1.90% in the previous three trading sessions and 8.49% in the last three months, outperforming the S&P 500 which has gained 1.35% and 2.87% during the respective periods. Moreover, the company' stock is trading above its 50-day and 200-day moving averages of $43.09 and $38.63 respectively. A free report on FRX can be accessed by registering at: http://www.AAAResearchReports.com/FRX090613.pdf Shares in Peregrine Pharmaceuticals Inc. rose sharply on Thursday, extending their gains from previous trading sessions. The company's shares vacillated between$1.41 and$1.45before finishing the day 2.13% higher at$1.44. A total of 1.45 million shares were traded, which is below the daily average volume of 1.73 million. Peregrine Pharmaceuticals Inc.'s shares have advanced 5.11% in the last three trading sessions, compared to a gain of 1.35% in the S&P 500 during the same period. Furthermore, the company's stock is trading above its 50-day moving average of $1.43. Register with AAA Research Reports and download research on PPHM for free at: http://www.AAAResearchReports.com/PPHM090613.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. http://AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 - Contact Name: Peter F. Jones - Email ID: firstname.lastname@example.org
Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc.
Press spacebar to pause and continue. Press esc to stop.